Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

Lancet Oncology

Volumn 8, Issue 1, 2007, Pages 21-25

  D'Amico, Anthony V ^a   Roehrborn, Claus G ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ALOPECIA; ANDROGENS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33845615437     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70981-0     Document Type: Article

References (16)

1. McConnell J., Roehrborn C., Bautista O., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
2. Marks L., Andriole G., Fitzpatrick J., et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 176 (2006) 868-874
3. US product circular for Propecia (finasteride 1 mg tablets) (October, 2004). In: Physicians' Desk Reference Electronic Library, Thomson Micromedex.
4. Guess H., Heyse J., Gormley G., et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: Results from the North American Phase III clinical trial. Urol Clin North Am 20 (1993) 627-636
5. Kaufman K., Olsen E., Whiting D., et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39 (1998) 578-589
6. Roehrborn C., Fuh V., Ruane P., et al. for the Finasteride 1 mg PSA Study Group. Effect of finasteride 1 mg versus placebo over 48 weeks on serum PSA in men age 40-60 years with androgenetic alopecia and no known prostatic disorder. J Urol 163 (2000) 220 (abstr 977)
7. Thompson I., Goodman P., Tangen C., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
8. de Koning H., Liem M., Baan C., et al. ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98 (2002) 268-273
9. Andriole G., Reding D., Hayes R., et al. PLCO Steering Committee. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol 22 (2004) 358-361
10. D'Amico A., and Barry M. Finasteride and prostate cancer prevention. J Urol 176 (2006) 2010-2013
11. Kulkarni G., Al-Azab R., Lockwood G., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505-509
12. Thompson I., and Lucia M. Diagnosing prostate cancer: through a glass, darkly. J Urol 175 (2006) 1598-1599
13. Thompson I., Chi C., Ankerst D., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
14. Etzioni R., Howlader N., Shaw P., et al. Long-term effects of finasteride on prostate specific antigen levels: results for the prostate cancer prevention trial. J Urol 174 (2005) 877-881
15. Grubb RL, Levin DL, Pinsky PF, et al. Relationship of PSA velocity and Gleason score in the PLCO Cancer Screening Trial. 2006 Annual Meeting of the American Urological Association; Atlanta, GA, USA; May 20-25, 2006 (abstr 522).
16. D'Amico AV, Cullen J, Chen Y, McLeod DG. Prostate-specific antigen velocity and the odds of identifying prostate cancer at biopsy. 2006 Annual Meeting of the American Urological Association; Atlanta, GA, USA; May 20-25, 2006 (abstr 523).